$0.33
0.61% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US0977021049
Symbol
BOLT
Sector
Industry

Bolt Biotherapeutics Inc Stock price

$0.33
-0.01 3.31% 1M
-0.24 42.16% 6M
-0.21 38.39% YTD
-0.46 58.27% 1Y
-1.30 79.77% 3Y
-31.82 98.97% 5Y
-31.82 98.97% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.61%
ISIN
US0977021049
Symbol
BOLT
Sector
Industry

Key metrics

Market capitalization $12.64m
Enterprise Value $-2.27m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.04
EV/Sales (TTM) EV/Sales -0.62
P/S ratio (TTM) P/S ratio 3.47
P/B ratio (TTM) P/B ratio 0.27
Revenue growth (TTM) Revenue growth -67.87%
Revenue (TTM) Revenue $3.64m
EBIT (operating result TTM) EBIT $-63.26m
Free Cash Flow (TTM) Free Cash Flow $-57.94m
Cash position $39.62m
EPS (TTM) EPS $-1.66
P/E forward negative
P/S forward 3.45
EV/Sales forward negative
Short interest 0.69%
Show more

Is Bolt Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Bolt Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Bolt Biotherapeutics Inc forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Bolt Biotherapeutics Inc forecast:

Buy
20%
Hold
80%

Financial data from Bolt Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.64 3.64
68% 68%
100%
- Direct Costs 1.72 1.72
34% 34%
47%
1.92 1.92
78% 78%
53%
- Selling and Administrative Expenses 15 15
27% 27%
404%
- Research and Development Expense 49 49
20% 20%
1,339%
-62 -62
15% 15%
-1,691%
- Depreciation and Amortization 1.72 1.72
34% 34%
47%
EBIT (Operating Income) EBIT -63 -63
16% 16%
-1,738%
Net Profit -63 -63
1% 1%
-1,740%

In millions USD.

Don't miss a Thing! We will send you all news about Bolt Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bolt Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
8 days ago
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We continue to make progress advancing our pipeline of first-in-class, novel immunotherapi...
Neutral
GlobeNewsWire
13 days ago
Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m.
Neutral
GlobeNewsWire
20 days ago
CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPs PD-L1 ISAC directly activates and reprograms PD-L1-expressing myeloid cells in the TME to drive complete responses and immunological memory REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for ...
More Bolt Biotherapeutics Inc News

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Head office United States
CEO William Quinn
Employees 52
Founded 2015
Website www.boltbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today